The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment option for patients suffering from a range of diseases including rheumatoid arthritis, psoriasis, ulcerative colitis and Crohn’s disease, says GBMA. A biosimilar is a biological
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.